Flutter Over Biocon’s Repurposed Psoriasis Drug For COVID-19 In India
Emergency Use But Some Concern Over Small Trial
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
You may also be interested in...
The granting of fast-track status is a clear signal that the US FDA wants to maintain its high standards of drug and vaccine appraisal.
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.